Observation on the Effect of Jinshuibao Combined with Levocarnitine in the Treatment of Patients with Chronic Renal Failure
Objective To investigate the clinical efficacy of using jinshuibao with levocarnitine in patients with chronic renal failure(CRF).Methods Sixty-eight patients with CRF admitted to the First Affiliated Hospital of Henan University of Science and Technology from January 2021 to July 2022 were selected,according to the random number table method divided into two groups.All patients were treated with haemodialysis after admission,the control group(34 cases)was treated with intravenous levocarnitine injection,and the observation group(34 cases)was treated with oral jinshuibao tablets on the basis of this treatment,which lasted for 10 weeks.The clinical efficacy,renal function indexes[blood creatinine(Scr),urea nitrogen(BUN),endogenous creatinine clearance(Ccr)],inflammatory factors[brain tumour necrosis factor-α(TNF-α),interleukin-6(IL-6),C-reactive protein(CRP)],nutritional indexes,and adverse reactions of the two groups were compared.Results Compared with the control group,the observation group had a higher total effective rate,lower Scr and BUN,higher Ccr,lower levels of TNF-α,IL-6 and CRP,and higher levels of total protein,albumin and haemoglobin,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the comparison of adverse reactions between the two groups(P>0.05).Conclusion The use of jinshuibao and levocarnitine in the treatment of CRF maintenance haemodialysis patients has remarkable clinical efficacy and has certain application and promotion value.
Chronic renal failureJinshuibaoLevocarnitineRenal functionInflammatory responseNutritional status
NETL
NSTL
万方数据
